VLP Diagnostics & Vaccine for Rat Hepatitis E Virus
Virus Like Particles (VLP) for the Diagnosis of and Protection Against Rat Hepatitis E Infection
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology leverages virus-like particles (VLPs) to improve the diagnosis and prevention of rat hepatitis E virus (HEV-C) infections, which existing tests and vaccines fail to address. The VLP-based antibody test can accurately detect and differentiate between human (HEV-A) and rat hepatitis E infections using common formats like ELISA and Western Blot. Additionally, the VLP (HEV-C1 p241) demonstrates immunogenicity in rats and shows potential as a vaccine for humans against rat hepatitis E. Applications include diagnostic tools and vaccines for global hepatitis E virus management, addressing a significant unmet need. Protected by a PCT patent application, this innovation offers a new solution for tackling hepatitis E's diverse strains.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Diagnostics & Screening; Vaccines
